A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease

Behavioural Brain Research

Volumn 222, Issue 1, 2011, Pages 89-97

  Bonardi, Charlotte ^a   de Pulford, Felicity ^a   Jennings, Dómhnall ^b   Pardon, Marie Christine ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Alzheimer's disease; Associative learning; Context extinction; Early Alzheimer's like cognitive changes; Mouse model

Indexed keywords

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; FEAR; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; STIMULUS RESPONSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ASSOCIATION LEARNING; CONDITIONING, CLASSICAL; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; HUMANS; LEARNING DISORDERS; MICE; MICE, TRANSGENIC; PRESENILIN-1; REACTION TIME; RETENTION (PSYCHOLOGY);

EID: 79953855775     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.03.041     Document Type: Article

References (58)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 2001, 81:741-766.
2. Krenz C., Larson E.B., Buchner D.M., Canfield C.G. Characterizing patient dysfunction in Alzheimer's-type dementia. Medical Care 1988, 26:453-461.
3. Price D.L., Whitehouse P.J., Struble R.G. Alzheimer's disease. Annual Review of Medicine 1985, 36:349-356.
4. Kukull W.A., Higdon R., Bowen J.D., McCormick W.C., Teri L., Schellenberg G.D., et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Archives of Neurology 2002, 59:1737-1746.
5. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
6. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 1998, 4:97-100.
7. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research 2001, 891:42-53.
8. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. Journal of Neuroscience 2005, 25:5217-5224.
9. Pistell P.J., Zhu M., Ingram D.K. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 2008, 152:594-600.
10. Holcomb L.A., Gordon M.N., Jantzen P., Hsiao K., Duff K., Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behavior Genetics 1999, 29:177-185.
11. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. Journal of Clinical Investigation 2004, 114:1624-1634.
12. Smith D.L., Pozueta J., Gong B., Arancio O., Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:16877-16882.
13. Terry R.D. Alzheimer's disease and the aging brain. Journal of Geriatric Psychiatry and Neurology 2006, 19:125-128.
14. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology 1991, 30:572-580.
15. Castellani R.J., Zhu X., Lee H.G., Moreira P.I., Perry G., Smith M.A. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Reviews of Neurotherapeutics 2007, 7:473-485.
16. Lee M.K., Borchelt D.R., Kim G., Thinakaran G., Slunt H.H., Ratovitski T., et al. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nature Medicine 1997, 3:756-760.
17. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends in Neurosciences 2001, 24:219-224.
18. Shemer I., Holmgren C., Min R., Fulop L., Zilberter M., Sousa K.M., et al. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. The European Journal of Neuroscience 2006, 23:2035-2047.
19. Hu Y.S., Xu P., Pigino G., Brady S.T., Larson J., Lazarov O. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 mice. The Faseb Journal: Official Publication of the Federation of American Societies For Experimental Biology 2010, 24:1667-1681.
20. Perez S.E., Dar S., Ikonomovic M.D., DeKosky S.T., Mufson E.J. Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiology of Disease 2007, 28:3-15.
21. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of Disease 2006, 24:516-524.
22. Wang J., Tanila H., Puolivali J., Kadish I., van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiology of Disease 2003, 14:318-327.
23. Gao S., Hendrie H.C., Hall K.S., Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Archives of General Psychiatry 1998, 55:809-815.
24. Pardon M.C., Sarmad S., Rattray I., Bates T.E., Scullion G.A., Marsden C.A., et al. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels. Neurobiology of Aging 2009, 30:1099-1113.
25. Rattray I., Pitiot A., Lowe J., Auer D.P., Lima S.J., Schubert M.I., et al. Novel cage stress alters remote contextual fear extinction and regional T2 magnetic resonance relaxation times in TASTPM mice overexpressing amyloid. Journal of Alzheimers Disease 2010, 20:1049-1068.
26. Rattray I., Scullion G.A., Soulby A., Kendall D.A., Pardon M.C. The occurrence of a deficit in contextual fear extinction in adult amyloid-over-expressing TASTPM mice is independent of the strength of conditioning but can be prevented by mild novel cage stress. Behavioural Brain Research 2009, 200:83-90.
27. Scullion G.A., Kendall D.A., Marsden C.A., Sunter D., Pardon M.C. Chronic treatment with the alpha(2)-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 2010.
28. Bonardi C., Bartle C., Bowles K., de Pulford F., Jennings D.J. Some appetitive procedures for examining associative learning in the mouse: implications for psychopathology. Behavioural Brain Research 2010, 211:240-247.
29. Pardon M.-C., Kendall D.A., Perez-Diaz F., Duxon M.S., Marsden C.A. Repeated sensory contact with aggressive mice rapidly leads to an anticipatory increase in core body temperature and physical activity that precedes the onset of aversive responding. The European Journal of Neuroscience 2004, 20:1033-1050.
30. Scullion G.A., Kendall D.A., Marsden C.A., Sunter D., Pardon M.C. Chronic treatment with the alpha(2)-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 2011, 60:223-234.
31. Scullion G.A., Kendall D.A., Sunter D., Marsden C.A., Pardon M.C. Central noradrenergic depletion by DSP-4 prevents stress-induced memory impairments in the object recognition task. Neuroscience 2009, 164:415-423.
32. Pearce J.M., Hall G. A model for Pavlovian learning: variations in the effectiveness of conditioned but not of unconditioned stimuli. Psychological Review 1980, 87:532-552.
33. Lubow R.E., Moore A.U. Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. Journal of Comparative and Physiological Psychology 1959, 52:415-419.
34. McGuinness B., Barrett S.L., Craig D., Lawson J., Passmore A.P. Attention deficits in Alzheimer's disease and vascular dementia. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:157-159.
35. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends in Neurosciences 1991, 14:220-223.
36. Rochford J., Sen A.P., Quirion R. Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. The Journal of Pharmacology and Experimental Therapeutics 1996, 277:1267-1275.
37. Melnikova T., Savonenko A., Wang Q., Liang X., Hand T., Wu L., et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006, 141:1149-1162.
38. Jardanhazi-Kurutz D., Kummer M.P., Terwel D., Vogel K., Dyrks T., Thiele A., et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochemistry International 2010, 57:375-382.
39. Ognibene E., Middei S., Daniele S., Adriani W., Ghirardi O., Caprioli A., et al. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behavioural Brain Research 2005, 156:225-232.
40. Assini F.L., Duzzioni M., Takahashi R.N. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behavioural Brain Research 2009, 204:206-211.
41. Murai T., Okuda S., Tanaka T., Ohta H. Characteristics of object location memory in mice: behavioral and pharmacological studies. Physiology and Behavior 2007, 90:116-124.
42. Oliveira A.M., Hawk J.D., Abel T., Havekes R. Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. Learning and Memory (Cold Spring Harbor, N.Y.) 2010, 17:155-160.
43. Bertaina-Anglade V., Enjuanes E., Morillon D., Drieu la Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. Journal of Pharmacological and Toxicological Methods 2006, 54:99-105.
44. Yoshiike Y., Kimura T., Yamashita S., Furudate H., Mizoroki T., Murayama M., et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One 2008, 3:e3029.
45. Donkin J.J., Stukas S., Hirsch-Reinshagen V., Namjoshi D., Wilkinson A., May S., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. The Journal of Biological Chemistry 2011, 285:34144-34154.
46. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Research 2004, 1017:130-136.
47. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
48. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behavioral Neuroscience 1992, 106:274-285.
49. Myers K.M., Davis M. Mechanisms of fear extinction. Molecular Psychiatry 2007, 12:120-150.
50. Konorski J. Integrative activity of the brain: An interdisciplinary approach 1967, University of Chicago Press.
51. Mackintosh N.J. Conditioning and associative learning 1983, Oxford University Press.
52. Brasted P.J., Bussey T.J., Murray E.A., Wise S.P. Role of the hippocampal system in associative learning beyond the spatial domain. Brain 2003, 126:1202-1223.
53. Sotres-Bayon F., Cain C.K., LeDoux J.E. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biological Psychiatry 2006, 60:329-336.
54. Quirk G.J., Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008, 33:56-72.
55. Radulovic J., Tronson N.C. Molecular specificity of multiple hippocampal processes governing fear extinction. Reviews in the Neurosciences 2010, 21:1-17.
56. Rickert E.J., Duke L.W., Putzke J.D., Marson D.C., Graham K. Early stage Alzheimer's disease disrupts encoding of contextual information. Aging, Neuropsychology, and Cognition 1998, 5:73-81.
57. Salmon D.P., Bondi M.W. Neuropsychological assessment of dementia. Annual Review of Psychology 2009, 60:257-282.
58. Tatham T.A., Zurn K.R. The Med-PC experimental apparatus programming system. Behavioral Research Methods, Instruments, and Computers 1989, 21:294-302.